Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential
László Radnai, Erica J. Young, Carlos Massayuki Kikuti, Katalin Tóth, Minghai Zhou, Madalyn Hafenbreidel, Rebecca F. Stremel, Lin Li, Paolo Pasetto, Xiaomin Jin, Aagam Patel, Michael P. Conlon, Sherri B. Briggs, Leïla Heidsieck, Hugh Lee Sweeney, , Courtney A. Miller
This paper develops a selective non-muscle myosin II inhibitor, MT-228, with high brain penetration and efficacy in preclinical models, offering therapeutic potential for diseases like stimulant use disorder.
Cell · Oct 7, 2024Peer-reviewedCell Biology